Brain-computer interfaces (BCIs) — implants that link the brain to computers — are going mainstream, with companies like Neuralink, Synchron, and Precision Neuroscience testing applications that help restore speech and movement in patients with strokes, Parkinson's, and spinal cord injuries. But a new report from the National Security Commission on Emerging Biotechnology warns that the U.S. is losing ground to China, which has already issued what's believed to be the world's first commercial BCI approval and designated the technology a national "future industry."

The commission points to regulatory bottlenecks and funding shortfalls as key culprits, noting that new neurological treatments take an average of over 11 years to reach FDA approval. It's calling on the FDA to create a clearer market pathway for implants and on CMS to establish reimbursement mechanisms — and eyes are on whether BCIs will be included in the Trump administration's RAPID program for breakthrough devices.

Key Takeaways:

• China's National Medical Products Administration issued what's believed to be the world's first commercial BCI approval this spring, for restoring hand movement in spinal cord injury patients
• The commission urges the FDA to streamline BCI approval pathways and CMS to develop coverage frameworks
• Privacy gaps are a major concern — existing laws like HIPAA may not cover neural data, and China currently has no neural-data-specific regulations
• BCIs could eventually extend beyond medicine into military and AI applications

Why it matters: BCIs hold transformative potential for patients with debilitating neurological conditions, but regulatory and funding inertia in the U.S. risks ceding both the clinical and strategic high ground to China.